id:"swepub:oai:prod.swepub.kib.ki.se:137567904"
Search: id:"swepub:oai:prod.swepub.kib.ki.se:137567904" > Menopausal hormone ...
- 1 of 1
- Previous record
- Next record
- To hitlist
Menopausal hormone therapy and colorectal cancer: a linkage between nationwide registries in Norway
- Botteri, E (author)
- Stoer, NC (author)
- Sakshaug, S (author)
- show more...
- Graff-Iversen, S (author)
- Vangen, S (author)
- Hofvind, S (author)
- de Lange, T (author)
- Bagnardi, V (author)
- Ursin, G (author)
- show less...
- (creator_code:org_t)
- 2017-11-15
- 2017
- English.
- In: BMJ open. - : BMJ. - 2044-6055. ; 7:11, s. e017639-
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- With the present study, we aimed to investigate the association between menopausal hormone therapy (HT) and risk of colorectal cancer (CRC).SettingCohort study based on the linkage of Norwegian population-based registries.ParticipantsWe selected 466822 Norwegian women, aged 55–79, alive and residing in Norway as of 1 January 2004, and we followed them from 2004 to 2008. Each woman contributed person-years at risk as non-user, current user and/or past HT user.Outcome measuresThe outcome of interest was adenocarcinoma of the colorectal tract, overall, by anatomic site and stage at diagnosis. Incidence rate ratios (RRs) with 95% CIs were estimated by Poisson regression and were used to evaluate the association between HT and CRC incidence.ResultsDuring the median follow-up of 4.8 years, 138 655 (30%) women received HT and 3799 (0.8%) incident CRCs occurred. Current, but not past, use of HT was associated with a lower risk of CRC (RR 0.88; 95% CI 0.80 to 0.98). RRs for localised, regionally advanced and metastatic CRC were 1.13 (95% CI 0.91 to 1.41), 0.81 (95% CI 0.70 to 0.94) and 0.79 (95% CI 0.62 to 1.00), respectively. RRs for current use of oestrogen therapy (ET) were 0.91 (95% CI 0.80 to 1.04) while RR for current use of combined oestrogen–progestin therapy (EPT) was 0.85 (95% CI 0.70 to 1.03), as compared with no use of HT. The same figures for ET and EPT in oral formulations were 0.83 (95% CI 0.68 to 1.03) and 0.86 (95% CI 0.71 to 1.05), respectively.ConclusionsIn our nationwide cohort study, HT use lowered the risk of CRC, specifically the most advanced CRC.
Publication and Content Type
- ref (subject category)
- art (subject category)
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Botteri, E
- Stoer, NC
- Sakshaug, S
- Graff-Iversen, S
- Vangen, S
- Hofvind, S
- show more...
- de Lange, T
- Bagnardi, V
- Ursin, G
- Weiderpass, E
- show less...
- Articles in the publication
- BMJ open
- By the university
- Karolinska Institutet
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
